2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 144

One-Year Costs Following Switching Versus Dose-Escalation Among Prevalent Tumor Necrosis Factor Inhibitors Used for Rheumatoid Arthritis
Abstract Number: 1672

One-Year Safety of Sirukumab Monotherapy: Results from a Randomized, Double-Blind, Parallel-Group, Multicenter Study in Japanese Subjects with Moderate to Severe Rheumatoid Arthritis
Abstract Number: 1295

Online Consultation for Rheumatic Disease Patients Based on Smart System of Disease Management (SSDM) Mobile Tools: A Study of Medical Economics
Abstract Number: 1230

Only One-Third of Patients with Spondyloarthritis Are Managed By Rheumatologists
Abstract Number: 1792

Optimal Monitoring for Coronary Heart Disease Risk in Systemic Lupus Erythematosus Patients: a Systematic Review
Abstract Number: 581

Optimization of Treatment Intervals of Tocilizumab and Golimumab By Measuring Serum Trough Levels in Rheumatoid Arthritis Patients
Abstract Number: 1220

Oral Glucocorticoid Prescribing Patterns in UK Primary Care for Patients with Rheumatoid Arthritis
Abstract Number: 51

Oral Glucocorticoid Use Is Associated with Osteonecrosis in Adults with Chronic Inflammatory Diseases but Not in Children: A Population-Based Cohort Study
Abstract Number: 1438

Oral Potassium (K+) Reduces Pain in RA: A Randomized Active Control Study of Diet Based K+ Intervention
Abstract Number: 3194

Oral to Subcutaneous Methotrexate Dose-Conversion Strategies in the Treatment of Rheumatoid Arthritis
Abstract Number: 723

Oral Ulcers in Systemic Lupus Erythematosus: Characterization and Clarification of an Important Clinical Manifestation
Abstract Number: 783

Osteonecrosis in Systemic Lupus Erythematosus: Predictive Factors
Abstract Number: 1702

Osteoporosis in Psoriatic Arthritis
Abstract Number: 380

Osteoporosis Screening and Treatment of Rheumatoid Arthritis Patients at a Teaching Institution
Abstract Number: 378

Osteoporotic Fragility Tibia/Fibula Fractures Are Not Asociated with a Low Body Mass Index: An Observational Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].